Search Results

First Patient Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Austria

https://www.cslbehring.de/news/2025/pm-hemgenix-first-patient-at

Researchers from Germany and Switzerland awarded

https://www.cslbehring.de/en-us/news/2022/seven-new-csl-global-research-acceleration-initiative-awardees-announced

Get to know us and learn more about people, projects and what happens in the world of CSL Behring.

https://www.cslbehring.de/en-us/news/2023/csl-big-mafex-pitch-day

Neue Preisträger:innen der CSL Global Research Acceleration Initiative bekannt gegeben.

https://www.cslbehring.de/news/2022/seven-new-csl-global-research-acceleration-initiative-awardees-announced

Get to know us and learn more about people, projects and what happens in the world of CSL Behring.

https://www.cslbehring.de/en-us/news/2022/visit-minister-jaala-pulford

Inspirierendes Networking für Wissenschaft und Gründerszene in der Region Marburg

https://www.cslbehring.de/news/2022/elevate-and-accelerate

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark

https://www.cslbehring.de/en-us/news/2025/pm-hemgenix-first-patients-denmark

CSL Behring Signs Milestone Commercial Agreement with Amgros to Fund Haemophilia B Gene Therapy HEMGENIX® in Denmark

https://www.cslbehring.de/en-us/news/2024/pm-agreement-amgros-denmark

CSL Behring ist weltweit führend im Bereich Biotechnologie mit dem Ziel, Leben zu retten und die Lebensqualität von Patienten zu verbessern.

https://www.cslbehring.de/nutzungsbedingungen

The new facility, once fully open later this calendar year, will be CSL’s largest R&D site under one roof, with more than 500 team members working in a state-of-the-art facility offering access to promising scientific partners and talent.

https://www.cslbehring.de/en-us/news/2022/csl-presents-new-research-and-development-center